ADVANCED BRAIN TUMOR
TREATMENT OPTIONS
Brain tumour treatment has moved far beyond surgery and conventional radiotherapy โ understanding the full option landscape, from SRS to BNCT to CAR-T, opens clinical possibilities that standard oncology teams may not be aware of.
analyticsAt a Glance
- check_circleTreatment is WHO grade and molecular marker-dependent โ not one-size-fits-all
- check_circleSRS/SBRT achieves high local control for brain metastases without craniotomy
- check_circleBNCT uniquely suited for recurrent glioma after prior RT
- check_circleCAR-T, oncolytic virus, and neoantigen vaccine trials active in China and India
Brain Tumours: Understanding What You Have
The term "brain tumour" encompasses biologically distinct entities โ from slow-growing benign meningiomas to highly aggressive GBM. Treatment, prognosis, and advanced option eligibility all depend on WHO grade, molecular profile, and tumour location.
Primary vs Metastatic Brain Tumours
Primary brain tumours arise from brain tissue itself โ gliomas (astrocytoma, oligodendroglioma, GBM), meningiomas, ependymomas, medulloblastomas. Metastatic brain tumours are secondary โ cancer from lung, breast, melanoma, renal, or colon spreading to the brain. Treatment strategies and advanced option eligibility differ significantly between primary and metastatic brain disease.
Why Molecular Markers Define Treatment
IDH mutation (grades 2โ3 glioma vs GBM); MGMT methylation (TMZ benefit in GBM); 1p/19q codeletion (oligodendroglioma โ responds to PCV chemotherapy); BRAF V600E (low-grade glioma โ vemurafenib eligible); H3K27M (diffuse midline glioma); EGFR amplification (GBM โ CAR-T trial eligibility). A comprehensive molecular profile is not optional for any brain tumour patient seeking advanced treatment.
Treatment Options by Brain Tumour Type
A summary of standard and advanced treatment options for the major brain tumour categories โ guiding patients and referring oncologists on what to explore.
| Tumour Type | Standard Treatment | Advanced Options | Key Biomarker |
|---|---|---|---|
| GBM (WHO Grade 4, IDH-wildtype) | Surgery + Stupp protocol (RT + TMZ) + TTFields | BNCT, CAR-T trials (EGFRvIII/GD2), oncolytic virus, neoantigen vaccines | MGMT methylation, EGFRvIII, IDH |
| IDH-mutant Grade 3โ4 glioma | Surgery + RT + PCV or TMZ | Vorasidenib (IDH1/2 inhibitor โ INDIGO trial); clinical trials | IDH1/2 mutation, 1p/19q |
| Oligodendroglioma (1p/19q codeleted) | Surgery + RT + PCV chemotherapy | Vorasidenib for IDH-mutant recurrence; PARP inhibitors in trials | 1p/19q codeletion, IDH mutation |
| Low-grade glioma (WHO Grade 2) | Surgery; deferred RT/chemo in selected cases | BRAF inhibitors (V600E mutant); IDH inhibitors; surveillance protocols | IDH, BRAF V600E, 1p/19q |
| Brain metastases (1โ3 lesions) | SRS (Gamma Knife/CyberKnife) ยฑ systemic targeted therapy | SRS + immunotherapy (anti-PD-1); WBRT with hippocampal avoidance; targeted therapy alone for driver-mutant primaries | Primary histology โ EGFR, ALK, BRAF, HER2 |
| Brain metastases (multiple) | WBRT or multiple-lesion SRS; systemic targeted therapy | Multiple-lesion SRS (>5 mets) with radiosurgery units; immunotherapy alone for select histologies (melanoma, NSCLC) | PD-L1, driver mutations |
| Meningioma (WHO Grade 1) | Surgery; SRS for small/residual tumours | Proton therapy for skull-base meningioma; clinical trials for recurrent | NF2, TRAF7, AKT1, KLF4 |
| Medulloblastoma | Surgery + craniospinal irradiation + chemotherapy | Proton CSI (reduces exit dose); vismodegib (SHH pathway); HDAC inhibitors in trials | SHH, WNT, Group 3/4 molecular subgroup |
Advanced Neurosurgical Techniques
Modern neurosurgery for brain tumours goes far beyond conventional resection โ specialised techniques improve extent of resection while preserving neurological function.
5-ALA Fluorescence-Guided Resection
5-aminolevulinic acid (5-ALA) is taken orally before surgery and selectively accumulates in high-grade glioma cells, causing them to fluoresce pink under blue light. The surgeon removes all fluorescent tissue โ significantly increasing complete resection rates for GBM (STUPP extension trial confirmed OS benefit). Available at major neurosurgical centres in China and India.
Awake Craniotomy
For tumours in or adjacent to eloquent cortex (language, motor, sensory areas), awake craniotomy allows intraoperative mapping of critical functions โ the patient performs tasks (counting, naming objects, moving limbs) while the surgeon maps safe resection boundaries. Maximises extent of resection while preventing permanent neurological deficit. Available at specialist neurosurgery centres in China and India.
Emerging Immunotherapy Approaches for Brain Tumours
Immunotherapy for brain tumours presents unique challenges โ the blood-brain barrier limits systemic drug delivery, and the CNS has an immunosuppressive microenvironment. Several innovative approaches are overcoming these barriers.
CAR-T Cell Therapy
GBM-directed CAR-T cells targeting EGFRvIII, IL13Rฮฑ2, GD2, and EGFRvIII ร CD19 bivalent constructs are in active Phase I/II trials. Intratumoral delivery (via Ommaya reservoir or convection-enhanced delivery) bypasses the BBB and delivers high local CAR-T concentrations directly to the tumour microenvironment. Chinese and US centres are leading early trials.
Neoantigen and Tumour Vaccines
Personalised neoantigen vaccines โ based on NGS-identified patient-specific tumour mutations โ are manufactured for each patient and given with immune adjuvants. DCVax-L (dendritic cell vaccine) demonstrated OS benefit in MGMT-methylated GBM in Phase III. Neoantigen vaccine trials are active in China and the USA.
Advanced Brain Tumour Treatment: Key Numbers
- 85โ95%Brain Met Local Control โ SRS (1โ3 Lesions)At 1 year for lesions treated with Gamma Knife or CyberKnife SRS
- ~15 moMedian OS โ BNCT for Recurrent GBM (Phase II)vs 6โ8 months historical control โ most compelling data for recurrent disease
- 21โ23 moMedian OS โ MGMT-Methylated GBM + TMZBest outcomes with standard Stupp + adjuvant TMZ in methylated patients
- Phase I/IIStatus of Most Advanced GBM TherapiesCAR-T, oncolytic virus, neoantigen vaccines โ all pre-Phase III; trial access critical
Related Neuro-Oncology Resources
In-depth guides on specific brain tumour treatments and access.
Frequently Asked Questions
Advanced Brain Tumour Treatment
What is the most important test to get after a brain tumour diagnosis?
The most important immediate step after a brain tumour diagnosis is a comprehensive molecular profile from the surgical specimen โ or from liquid biopsy if tissue is not available. The minimum panel should include: IDH1/2 mutation, MGMT promoter methylation status, 1p/19q codeletion, TERT promoter mutation, H3K27M (for midline tumours), EGFR amplification/EGFRvIII, and tumour mutational burden. These results determine WHO grade, prognosis, chemotherapy benefit prediction (MGMT for TMZ), and eligibility for targeted therapies and clinical trials. Without this information, treatment decisions are made in the dark.
Are there brain tumours where BNCT is specifically indicated?
Currently, the strongest BNCT evidence exists for: (1) recurrent head and neck cancer after prior RT (approved in Japan); (2) recurrent glioblastoma after prior chemoradiation โ Phase II data shows significantly longer OS than historical controls. BNCT is most appropriate when standard re-irradiation cannot be delivered due to prior RT dose constraints, or when small-molecule and immunotherapy options have been exhausted. It is not currently standard of care for newly diagnosed GBM, where Phase III trials are ongoing in Japan and China. CancerFax can assess BNCT candidacy based on prior treatment history and current disease status.
What is the difference between SRS and SBRT for brain tumours?
Stereotactic radiosurgery (SRS) typically refers to single-fraction treatment โ delivering the full ablative dose in one session (e.g. 18โ24 Gy ร 1). SBRT (stereotactic body radiation therapy) for brain targets uses 3โ5 fractions. SRS in 1โ3 fractions is preferred for brain metastases โค3โ4 cm and functional conditions (AVM, trigeminal neuralgia). Fractionated SRS/SBRT (3โ5 fractions) is preferred for larger tumours (>3 cm), tumours adjacent to critical structures (brainstem, optic chiasm), or re-irradiation cases where single-fraction dose cannot be safely delivered. The platform (Gamma Knife, CyberKnife, linear accelerator) does not determine the fractionation โ both approaches are available on multiple platforms.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Looking for Advanced Brain Tumour Treatment Options?
Upload your MRI, pathology, and molecular profile. CancerFax will assess advanced treatment eligibility and connect you with specialist neuro-oncologists in China or India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.